Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

This study is testing a combination of three targeted cancer drugs — trametinib, everolimus, and lenvatinib — in people with advanced solid tumors that have come back or stopped responding to prior treatments, to find a safe dose and see if the combination is effective. **You may be eligible if...** - You are between 18 and 85 years old - You have an advanced solid tumor (not a benign growth) that has returned or no longer responds to treatment - Your expected survival is more than 3 months - You are in acceptable general health **You may NOT be eligible if...** - Your tumor is benign - Your life expectancy is less than 3 months - You have serious other medical conditions Talk to your doctor to see if this trial is right for you.